0001564590-22-039439.txt : 20221219 0001564590-22-039439.hdr.sgml : 20221219 20221219060544 ACCESSION NUMBER: 0001564590-22-039439 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20221216 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221219 DATE AS OF CHANGE: 20221219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STAAR SURGICAL CO CENTRAL INDEX KEY: 0000718937 STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851] IRS NUMBER: 953797439 STATE OF INCORPORATION: DE FISCAL YEAR END: 1230 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11634 FILM NUMBER: 221469540 BUSINESS ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 BUSINESS PHONE: 6263037902 MAIL ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 FORMER COMPANY: FORMER CONFORMED NAME: STAAR SURGICAL COMPANY DATE OF NAME CHANGE: 19920703 8-K 1 staa-8k_20221216.htm 8-K staa-8k_20221216.htm
false 0000718937 0000718937 2022-12-16 2022-12-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): December 16, 2022

 

 

STAAR Surgical Company

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

0-11634

95-3797439

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

25651 Atlantic Ocean Drive

Lake Forest, California

 

92630

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

STAA

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 16, 2022, STAAR Surgical Company (the “Company”) announced that Ms. Caren Mason, President and Chief Executive Officer of the Company, has elected to retire as CEO and a member of the Company’s Board of Directors (the “Board”), effective December 31, 2022, after seven years successfully leading the Company.  

On December 16, 2022, the Company announced that the Board elected Thomas G. Frinzi, currently Chair of the Board, to succeed Ms. Mason as CEO, effective January 1, 2023. Mr. Frinzi has extensive experience in the ophthalmic and medical device industries at both large, well-established companies and innovative start-ups. He served as Worldwide President, Surgical for Johnson & Johnson’s Vision business, and previously served as Senior Vice President of Abbott Laboratories and President, Abbott Medical Optics (AMO). Prior to Abbott, he served as President and CEO of WaveTec Vision, a developer of surgical systems for eye surgery. He previously held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Chiron Vision. Additional biographical and other information required by this Item concerning Mr. Frinzi is included in the Company’s definitive proxy statement for the 2022 Annual Meeting of Shareholders, filed with the SEC on April 29, 2022. The Board has voted to reduce its size to six members following Ms. Mason’s retirement from the Board, effective December 31, 2022.

On December 16, 2022, the Board announced creation of the role of Lead Independent Director and appointed Mr. Stephen Farrell, Chair of the Audit Committee, to serve in that capacity.

In connection with his service as CEO, Mr. Frinzi and the Board entered into an employment agreement (the “Frinzi Agreement”) pursuant to which Mr. Frinzi will receive the following compensation as CEO: (i) base salary at an annual rate of $820,000, (ii) participation in the Company’s annual cash bonus program with a target bonus of 105% of his base salary, (iii) a new hire initial grant of equity with a grant date value of $9,000,000, (x) half of which consists of stock options a third of which will vest on the one year anniversary of employment and the remainder of which will vest at the rate of 1/24 per month over the following two years, and (y) half of which consists of restricted stock units, a third of which will vest on each of the first, second and third anniversaries of employment. Mr. Frinzi will participate in all other elements of the Company’s executive compensation and benefits plans. The Frinzi Agreement also provides for customary restrictive and confidentiality covenants. Mr. Frinzi will not receive any compensation as a director during his tenure as CEO.

To facilitate the smooth transition in leadership, Ms. Mason will serve as an Advisor to Mr. Frinzi, the Board and the executive management team through December 31, 2023. The Company’s Consulting Agreement with Ms. Mason compensates her at a rate of $100,000 per month. Ms. Mason will remain eligible for a cash bonus for 2022 performance, consistent with pre-established metrics for funding and awarding bonuses to executives for 2022 performance. Ms. Mason’s retirement is not the result of any dispute or disagreement with the Company, its Board, or its management, or any matter relating to the Company’s operations, policies or practices.

The summary herein is qualified in its entirety by reference to Mr. Frinzi’s Employment Agreement and Ms. Mason’s Consulting Agreement, copies of which are attached hereto as Exhibit 10.1 and 10.2, and are incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On December 16, 2022, the Company issued a press release announcing the management changes. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information set forth in the attached Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

 

Exhibit Number

  

Description

10.1

  

Frinzi Employment Agreement

 

 

10.2

  

Mason Consulting Agreement

 

 

99.1

  

Press Release dated December 19, 2022

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).


 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

STAAR Surgical Company 

 

December 19, 2022

By:

/s/ Caren Mason

 

 

Caren Mason

 

 

President and Chief Executive Officer

 

 

 

EX-10.1 2 staa-ex101_7.htm EX-10.1 staa-ex101_7.htm

Exhibit 10.1

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is entered into and effective as of January 1, 2023 (“Effective Date”), by and between STAAR Surgical Company, a Delaware corporation on behalf of itself and any and all affiliated entities (together, the “Company”) and Thomas G. Frinzi (“Executive”).  

RECITALS

A.

The Company is a leading developer, manufacturer and marketer of implantable lenses for the eye and delivery systems related thereto (the “Business”).

B.

The Company wishes to employ Executive to serve as its Chief Executive Officer.

C.

Executive wishes to be employed by the Company and to serve in such capacity under the terms and conditions in this Agreement.

NOW, THEREFORE, the parties agree as follows:

1.Position and Duties.

(a)During the term of this Agreement, Executive will be employed by the Company to serve as Chief Executive Officer of the Company, reporting to the Company’s Board of Directors (“Board”).  As Chief Executive Officer, Executive will, subject to the supervision and direction of the Board, be responsible for: (i) implementing goals, operating plans, policies and objectives for the Company; (ii) performing the duties and responsibilities customarily expected to be performed by a Chief Executive Officer; and (iii) performing such other duties and functions as are reasonably required and/or as may be reasonably prescribed by the Board from time-to-time.

(b)The location of Executive’s employment will be the Company’s headquarters offices, but Executive from time to time may be required to travel to other geographic locations in connection with the performance of his duties. Executive shall be permitted to work remotely Monday and Friday of each work week.

2.Standards of Performance.  Executive will at all times faithfully, industriously and to the best of his ability, experience and talents perform all of the duties required of and from him pursuant to the terms of this Agreement. Executive will devote his full business energies and abilities and all of his business time to the performance of his duties hereunder and will not, without the Company’s prior written consent, render to others any service of any kind (whether or not for compensation) that, in the Company’s sole but reasonable judgment, would interfere with the full performance of his duties hereunder. Notwithstanding the foregoing, Executive is permitted to spend reasonable amounts of time to manage his personal financial and legal affairs and, with the Company’s consent which will not be unreasonably withheld, to serve on civic, charitable, not-for-profit, industry or corporate boards or advisory committees, provided

 


that such activities, individually and collectively, do not materially interfere with the performance of Executives duties hereunder.  .In no event will Executive engage in any activities that could reasonably create a conflict of interest or the appearance of a conflict of interest. Executive shall be subject to the Companys policies, procedures and approval practices, as generally in effect from time to time.

3.Term.  Executive will be employed for no specific term and until terminated pursuant to the terms of this Agreement.  The Company and Executive shall each have a right to terminate this Agreement as provided in Section 5, below.  

4.Compensation, Benefits and Policies.

(a)Base Salary.  As an annual base salary (“Base Salary”) for all services rendered pursuant to this Agreement, Executive will be paid an initial Base Salary in the gross amount of eight hundred and twenty thousand dollars ($820,000) calculated on an annualized basis, less necessary withholdings and authorized deductions, and payable pursuant to the Company’s regular payroll practices at the time.  The Base Salary is subject to periodic review and adjustment not less frequently than annually within the first three (3) months after the end of each fiscal year, in the sole discretion of the Board.

(b)Performance Bonus.  During Executive’s employment under this Agreement, Executive will be eligible for a performance bonus, subject to the terms and conditions of the bonus plan applicable to senior executives of the Company, if any, established by the Board.  The target amount of the annual bonus is one hundred and five percent (105%) of Executive’s annual Base Salary.  However, payment of the bonus will be conditioned on the Company’s achievement of financial objectives established by the Board and individual performance objectives to be established annually by the Board, and the bonus may be zero. For the avoidance of doubt, the performance bonus will be payable only if financial and performance objectives established by the Board are achieved.  To encourage continued tenure with the Company, Executive must be employed by the Company as of the payment date to be eligible for a performance bonus for the year to which the bonus relates.  Performance bonuses will be paid out according to the terms of the applicable bonus plan, if any, but in no event later than the end of the first quarter of the year that immediately follows the fiscal year to which the bonus relates.

(c)Long Term Incentive Compensation.  Executive will be eligible to participate in the long term incentive plans applicable to senior executives of the Company as may be established by the Board from time to time, commencing with the 2024 equity grant cycle to management, subject to the terms and conditions of any such plans.  The incentive may vary from year to year, and may consist of restricted stock grants, stock options or other forms of incentive, or a combination of more than one type of incentive.  Subject to full execution of this Agreement, Executive will receive an option to purchase shares with a value of four and a half million dollars ($4,500,000) and also restricted stock options (RSUs) with a value of four and a half million dollars ($4,500,000) of STAAR Surgical Company’s common stock.  The grant will be effective and priced on January 2, 2023, provided that is Executive’s first day of employment and

-2-


this Agreement is fully executed. The options will vest in increments of one third on the first year anniversary, and 1/24 on a monthly basis thereafter.  All of these options shall have a ten year term after vesting.  In addition, the Executive will have twelve (12) months to exercise all of his vested stock options after termination of service with the Company, unless terminated by the Company with cause. The RSUs will vest in increments of one third on the first year anniversary, one third on the second year anniversary, and one third on the third year anniversary.

(d)Paid Time Off and Benefits. Executive is entitled to participate in any plans regarding benefits of employment, including pension, profit sharing, group health, disability insurance and other employee pension and welfare benefit plans now existing or hereafter established to the extent that Executive is eligible under the terms of such plans and if the other executive officers of the Company generally are eligible to participate in such plan.  The Company may, in its sole discretion and from time-to-time, establish additional senior management benefit plans as it deems appropriate.  Executive understands that any such plans may be modified or eliminated in the Company’s sole discretion in accordance with applicable law, provided that no such modification or elimination shall result in reducing or eliminating any benefits in which Executive’s right has vested.

(e)Reimbursement of Business Expenses.  The Company will promptly reimburse to Executive his reasonable, customary and documented out-of-pocket business expenses in connection with the performance of his duties under this Agreement, and in accordance with the policies and procedures established by the Company.  If such expense qualifies hereunder for reimbursement, then the Company will reimburse Executive for that expense in accordance with the Company’s policy

(f)Sarbanes-Oxley Act Loan Prohibition.  To the extent that any Company benefit, program, practice, arrangement or this Agreement would or might otherwise result in Executive’s receipt of an illegal loan (the “Loan”), the Company shall use commercially reasonable efforts to provide Executive with a substitute for the Loan that is lawful and of at least equal value to Executive.  If this cannot be done, or if doing so would be significantly more expensive to the Company than making the Loan, the Company need not make the Loan to Executive or provide him a substitute for it.

5.Termination of Employment.

(a)By Company Without Cause.  The Company may terminate Executive's employment without Cause (as defined in this Agreement) at any time and without prior notice, written or otherwise.  In the event the Company terminates Executive's employment for other than Cause, Incapacity (as defined in this Agreement) or death, and subject to the other provisions of this Agreement, Executive will be entitled to:

(i)continued coverage under the Company’s insurance benefit plans through the termination date and such other benefits to which he may be entitled pursuant to the Company’s benefit plans (other than any severance plan);

-3-


(ii)payment of all earned but unpaid compensation (including accrued unpaid vacation) through the effective date of termination, payable on or before the termination date; and

(iii)reimbursement of expenses incurred on or before the termination date in accordance with Section 4(e), above; plus

(iv)payment of the equivalent of the Base Salary he would have earned over the next eighteen (18) months following the termination date (less necessary withholdings and authorized deductions) at his then current Base Salary rate (the “Severance Payment”), payable in equal monthly installments over the eighteen (18) months following the termination date (the “Severance Period”), subject to Section 16, below; and

(v)at Executive’s option, reimbursement of insurance premiums payable to retain group health coverage as of the termination date for himself and his eligible dependents pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1986 (“COBRA”) for 18 (18) months.  

The payments and benefits set forth in Sections 5(a)(i)-(iii) shall be referred to as the “Accrued Benefits”, and the payments and benefits set forth in Sections 5(a)(iv)-(v) shall be referred to as the “Severance Benefits”.  Executive shall not receive the Severance Benefits unless Executive executes the separation agreement and general release attached as Exhibit A, and the same becomes effective pursuant to its terms.  In addition, if Executive accepts other full time employment within the Severance Period, the Company’s obligation under Section 5(a)(v) above will be extinguished as of the date Executive becomes covered under the group health plan of Executive’s new employer.

(b)By Company With Cause.  The Company may terminate Executive’s employment at any time and without prior notice, written or otherwise, for Cause.  As used in this Agreement, “Cause” shall mean any of the following conduct by Executive:  (i) material breach of this Agreement, or of a Company policy or of a law, rule or regulation applicable to the Company or its operations; (ii) demonstrated and material neglect of duties, or failure or refusal to perform the material duties of his position, or the failure to follow the reasonable and lawful instructions of the Board; (iii) dishonesty, self-dealing, fraud, misrepresentation, gross negligence or serious misconduct; or (iv) conviction of or plea of guilty or nolo contendere to any felony crime.  Termination pursuant to Section 5(b)(ii) shall be effective only if such failure continues after Executive has been given written notice thereof and fifteen (15) business days thereafter in which to present his position to the Board or to cure the same, unless the Board reasonably determines that the reason(s) for termination are not capable of being cured.  In the event of termination for Cause, Executive will be entitled only to the Accrued Benefits through the termination date, which will be the date on which the notice is given.  The Company will have no further obligation to pay any compensation of any kind (including without limitation any bonus or portion of a bonus that otherwise may have become due and payable to Executive with respect to the year in which such

-4-


termination date occurs), or severance payment of any kind nor to make any payment in lieu of notice.

(c)Incapacity or Death.

(i)Incapacity” means that Executive is (A) unable to perform the essential functions of his position, with or without reasonable accommodation, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, or (B) by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, and is receiving income replacement benefits for a period of not less than three months under an accident and health plan covering the Company's employees, or (C) determined to be totally disabled by the Social Security Administration, as interpreted by the Company in its discretion, or (D) deemed to be disabled in accordance with the applicable disability insurance program of the Company, provided that the definition of "disability" applied under such disability insurance program complies with the requirements of this subsection, as determined by the Company in its discretion.  A determination of Incapacity shall not be arbitrary or unreasonable and the Company, in making such determination, shall take into consideration the opinion of Executive's personal physician, if reasonably available, and any other physician deemed appropriate by the Company, but such determination by the Company shall be final and binding on the parties hereto.  The Company will provide all applicable legally-required leaves to Executive, which shall be provided on an unpaid basis unless pay is otherwise required under applicable law.  This provision shall be interpreted and applied in a manner consistent with all applicable laws, including laws regarding workers' compensation, reasonable accommodation of disability, and family and medical leave laws.  The Company has the right to terminate Executive’s employment for Incapacity on fifteen (15) days’ written notice.  In the event of termination for Incapacity, Executive will be entitled to receive the Accrued Benefits.

(ii)Executive’s employment pursuant to this Agreement shall be immediately terminated without notice by the Company upon the death of Executive.  If Executive dies while actively employed pursuant to this Agreement, the Company will pay the Accrued Benefits to his estate or designated beneficiaries within sixty (60) days.

(d)Resignation for Good Reason.  Executive may resign and terminate this Agreement for Good Reason (as defined below) by giving written notice of resignation to the Company.  As used in this Agreement, “Good Reason” shall mean any one of the following:  (i) a material reduction in Executive’s Base Salary and/or a material failure to provide the benefits required in Section 4, (ii) any action or inaction that constitutes a material breach by the Company of this Agreement; (iii) a material diminution in Executive’s authority, duties or responsibilities such that they are materially inconsistent with his position as Chief Executive Officer of the Company; and (iv) relocation of the Company’s headquarters to a location that materially increases Executive’s commute.  Resignation for Good Reason shall not be effective unless all of the following conditions are satisfied: (A) Executive has given the Company written notice (pursuant to Section 11

-5-


below) within thirty (30) days of the initial occurrence of any of the above-specified events or conditions constituting the Good Reason and has requested a specific reasonable cure, (B) the Company has failed to cure the occurrence within thirty (30) days of receiving written notice from Executive (the “Cure Period”), and (C) Executive provides written notice of a resignation date that is after the expiration of the Cure Period but no more than ninety (90) days after the initial occurrence of the event giving rise to the resignation for Good Reason.  In the event of a resignation for Good Reason, Executive will be entitled to the Accrued Benefits and the Severance Benefits, on the same conditions set forth in the final paragraph of Section 5(a), specifically including, but not limited to, the signing of the severance agreement and general release document, attached hereto as Exhibit A except that any Severance Payment shall in no event be less than the Executive Base Salary set forth in paragraph 4 (a) above.

(e)Resignation or Termination Following a Change in Control.  Executive may resign and terminate this Agreement following a Change in Control (as defined below) if the successor to the Company fails to offer or maintain Executive in the position of Chief Executive Officer of the successor company reporting to the Board of the successor to the Company, with compensation and benefits substantially similar to those enjoyed by Executive immediately preceding the Change in Control for a period of eighteen (18) months following the Change in Control.  Resignation following a Change in Control shall not be effective unless all of the following conditions are satisfied: (A) Executive has given the Company written notice (pursuant to Section 11 below) within thirty (30) days of the change in position and/or compensation and benefits and has requested a specific reasonable cure, (B) the Company has failed to restore Executive’s position and/or compensation and benefits within thirty (30) days of receiving written notice from Executive, and (C) Executive provides written notice of a resignation date that is after the time for the Company to restore Executive’s position and/or compensation and benefits has expired, but no more than ninety (90) days after the change in position and/or compensation and benefits.  In the event of Executive’s resignation following a Change in Control in accordance with this subsection, or if the Company terminates Executive without Cause within twelve (12) months after a Change in Control, subject to the same conditions set forth in the final paragraph of Section 5(a), specifically including, but not limited to, the signing of the severance agreement and general release document, attached hereto as Exhibit A, Executive will be entitled to the Accrued Benefits and the Severance Benefits, plus an amount equal to his bonus, if any, for the year prior to his resignation or termination and an amount equal to his target bonus for the year in which his resignation or termination occurs. In no event will any Severance Payment be less than the Executive Base Salary set forth in paragraph 4 (a) above. In such event, STAAR agrees that all stock options, restricted stock and other incentive compensation awards of the Executive that are outstanding at the time of such termination and that have not previously become exercisable, payable or free from restrictions shall immediately become exercisable, payable or free from restrictions, as the case may be, in their entirety, and that, the exercise period of any stock option shall continue for the length of the exercise period specified in the grant of the award determined without regard to the Executive’s termination of employment (collectively, the “Change in Control Benefits”).

-6-


As used in this Agreement, a “Change in Control” shall mean any of the following events:

(i)any person, including a group as defined in Section 13(d)(3) of the Securities Exchange Act of 1934 (the “1934 Act”), but excluding Broadwood Partners, L.P. or a group of which it is a member, becomes the beneficial owner of stock of the Company with respect to which twenty-five percent (25%) or more of the total number of votes for the election of the Board may be cast;

(ii)as a result of, or in connection with, any cash tender offer, exchange offer, merger or other business combination, sale of assets or contested election, or combination of the foregoing, persons who were directors of the Company just prior to such event shall cease to constitute a majority of the Board;

(iii)the stockholders of the Company approve an agreement providing either for a transaction in which the Company will cease to be an independent publicly owned corporation or for a sale or other disposition of all or substantially all the assets of the Company;

(iv)acquisition in a single or series of related transactions, including without limitation a tender offer or exchange offer, by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company's outstanding securities; or

(v)any other event that a majority of the incumbent Board in its sole discretion determines to be a Change in Control.

Notwithstanding the foregoing, the formation of a holding company for the Company in which the stockholdings of the holding company after its formation are substantially the same as for the Company prior to the holding company formation does not constitute a Change in Control for purposes of this Agreement.

(f)Voluntary Resignation without Good Reason.  Executive may terminate this Agreement without Good Reason effective on sixty (60) day’s written notice, unless the Company in its sole discretion accepts the resignation earlier.  In the event that Executive resigns without Good Reason as defined above in Section 5(d), Executive will be entitled only to the Accrued Benefits through the termination date.  The Company will have no further obligation to pay any compensation of any kind (including without limitation any bonus or portion of a bonus that otherwise may have become due and payable to Executive with respect to the year in which such termination date occurs), or severance payments of any kind.  

6.Proprietary Information Obligations.

(a)Proprietary Information and Confidentiality.  Both before and during the term of Executive’s employment, Executive will have access to and become acquainted

-7-


with certain confidential and/or proprietary information regarding the Company and its Business, including, without limitation, all of the following materials and information (whether or not reduced to writing and whether or not patentable or protected by copyright):  trade secrets; inventions; processes; formulae; programs; technical data; products; sales and marketing plans; financial information; Company-developed software; engineering designs and documentation; customer proposals, specifications and requirements; identities, lists and confidential information about customers, prospects, suppliers, vendors and key employees; personal information relating to the Company’s employees; mailing and e-mail lists (collectively, “Proprietary Information”).  Executive will not disclose any of the Proprietary Information directly or indirectly, or use it in any way, either during his employment pursuant to this Agreement or at any time thereafter, except as reasonably required or specifically requested in the course of his employment with the Company or as authorized in writing by the Company.  Notwithstanding the foregoing, Proprietary Information does not include information that is otherwise publicly known or available, provided it has not become public as a result of a breach of this Agreement, or any other agreement Executive has or may have to keep information confidential.  It is not a breach of this Agreement for Executive to disclose Proprietary Information pursuant to an order of a court or other governmental or legal body.

(b)Inventions Agreement and Assignment.

(i)Executive hereby agrees to disclose promptly to the Company (or any persons designated by it) all developments, designs, creations, improvements, original works of authorship, formulas, processes, know-how, techniques and/or inventions (collectively, the “Inventions”) (A) which are made or conceived or reduced to practice by Executive, either alone or jointly with others, in performing his duties during the period of Executive’s employment by the Company, that relate to or are useful in the business of the Company; or (B) which result from tasks assigned to Executive by the Company, or from Executive’s use of the premises or other resources owned, leased or contracted by the Company.

(ii)Executive agrees that all such Inventions which the Company in its discretion determines to be related to or useful in its business or its research or development, or which result from work performed by Executive for the Company, will be the sole and exclusive property of the Company and its assigns, and the Company and its assigns will have the right to use and/or to apply for patents, copyrights or other statutory or common law protections for such Inventions in any and all countries.  Executive further agrees to assist the Company in every reasonable way (but at the Company’s expense) to obtain and from time to time enforce patents, copyrights and other statutory or common law protections for such Inventions in any and all countries.  To that end, Executive will execute all documents for use in applying for and obtaining such patents, copyrights and other statutory or common law protections therefor and enforcing the same, as the Company may desire, together with any assignments thereof to the Company or to persons or entities designated by the Company.  Should the Company be unable to secure Executive’s signature on any document necessary to apply for, prosecute, obtain, or enforce any patent, copyright or other right or protection relating to any Invention, whether due to his mental or physical incapacity or any other cause,

-8-


Executive hereby irrevocably designates and appoints the Company and each of its duly authorized officers and agents as Executive’s agent and attorney-in-fact, to act for and in his behalf and stead, to execute and file any such document, and to do all other lawfully permitted acts to further the prosecution, issuance, and enforcement of patents, copyrights or other rights or protections with the same force and effect as if executed and delivered by Executive.  Executive’s obligations under this Section 6(b)(ii) will continue beyond the termination of Executive’s employment with the Company, but the Company will compensate Executive at a reasonable rate after such termination for time actually spent by Executive at the Company’s request in providing such assistance.

(iii)Executive hereby acknowledges that all original works of authorship which are made by Executive (solely or jointly with others) within the scope of Executive’s employment which are protectable by copyright are “works for hire,” as that term is defined in the United States Copyright Act (17 U.S.C. section 101).

(iv)Any provision in this Agreement requiring Executive to assign Executive’s rights in any Invention to the Company will not apply to any invention that is exempt under the provisions of California Labor Code section 2870, which provides:

“(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:  (1) relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or (2) result from any work performed by the employee for the employer.  (b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.”

(c)[Intentionally omitted.]    

(d)Non-Solicitation of Employees.  Executive recognizes the substantial expenditure of time and effort which the Company devotes to the recruitment, hiring, orientation, training and retention of its employees.  Accordingly, Executive agrees that, for a period beginning on the Effective Date and ending twelve (12) months after termination of Executive’s employment with the Company, regardless of the reason for such termination, Executive shall not use any Proprietary Information, directly or

-9-


indirectly, for himself or on behalf of any other person or entity, solicit, offer employment to, hire or otherwise retain the services of any employee of the Company in a position classified as exempt from overtime pay requirements.  For purposes of the foregoing, “employee of the Company” shall include any person who was an employee of the Company at any time within six (6) months prior to the prohibited conduct.  

(e)Company Property and Materials.  

(i)All files, records, documents, computer-recorded or electronic information, drawings, specifications, equipment, and similar items relating to Company business, whether prepared by Executive or otherwise coming into his possession, will remain the Company’s exclusive property and will not be removed from Company premises under any circumstances whatsoever without the Company’s prior written consent, except when, and only for the period, necessary to carry out Executive’s duties hereunder

(ii)In the event of termination of Executive’s employment for any reason, Executive will promptly deliver to the Company all Company equipment (including, without limitation, any laptop and/or tablet computers, cellular phones or other devices, and computer hardware and software) and all originals and electronic or physical copies of all documents, including without limitation, all books, customer lists, forms, documents supplied by customers, records, product lists, writings, manuals, reports, financial documents and other documents or property in Executive’s possession or control, which relate to the Company’s business in any way whatsoever, and in particular to customers of the Company, or which may be considered to constitute or contain Proprietary Information as defined above, and Executive will neither retain, reproduce, nor distribute copies thereof (other than a copy, prepared or reviewed and approved by the Company, of Executive’s contacts in Outlook or similar electronic or physical copy address and telephone directory).

(f)Remedies for Breach. Executive acknowledges that any breach by Executive of this Section 6 would cause the Company irreparable injury and damage for which monetary damages are inadequate.  Accordingly, in the event of a breach or a threatened breach of this Section 6, the Company will be entitled to an injunction restraining such breach.  In addition, in the event of a breach of this Section 6, the Company’s obligation to pay any unpaid portion of the Severance Payment or other benefits as set forth in Sections 5(a), (d) and (e) of this Agreement will be extinguished.  Nothing contained herein will be construed as prohibiting the Company from pursuing any other remedy available to the Company for such breach or such threatened breach.  Executive has carefully read and considered these restrictions and agrees they are fair and reasonable restrictions on Executive and are reasonably required for the protection of the interests of the Company.  Executive agrees not to circumvent the spirit of these restrictions by attempting to accomplish indirectly what Executive is otherwise restricted from doing directly.  Executive agrees that the restrictions in this Section 6 are reasonable and necessary to protect the Company’s Proprietary Information, and they do not prevent Executive from working in the medical device industry.  To the extent that any of the provisions in this Section 6 are held to be overly broad or otherwise unenforceable at the

-10-


time enforcement is sought, Executive agrees that the provision shall be reformed and enforced to the greatest extent permissible by law.  Executive further agrees that if any portion of this Section 6 is held to be unenforceable, the remaining provisions of this Section 6 shall be enforced as written.  

7.Interpretation, Governing Law and Exclusive Forum.  The validity, interpretation, construction, and performance of this Agreement shall be governed by the laws of the State of California (excluding any that mandate the use of another jurisdiction’s laws).  Any arbitration (unless otherwise mutually agreed), litigation or similar proceeding with respect to such matters only may be brought within the County of Orange, state of California, and all parties to this Agreement consent to California’s jurisdiction.

8.Entire Agreement.  All oral or written agreements or representations, express or implied, with respect to the subject matter of this Agreement are set forth in this Agreement.

9.Severability.  In the event that one or more of the provisions contained in this Agreement are held to be invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, such holding shall not impair the validity, legality or enforceability of the remaining provisions herein.

10.Successors and Assigns.  This Agreement shall be binding upon, and shall inure to the benefit of, Executive and his estate, but Executive may not assign or pledge this Agreement or any rights arising under it, except to the extent permitted under the terms of the benefit plans in which he participates.  No rights or obligations of the Company under this Agreement may be assigned or transferred except that the Company shall require any successor (whether direct or indirect, by purchase, merger, reorganization, sale, transfer of stock, consideration or otherwise) to all or substantially all of the business and/or assets of the Company to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no succession had taken place.  As used in this Agreement, “Company” means the Company as hereinbefore defined and any successor to its business and/or assets (by merger, purchase or otherwise as provided in this Section 10) which executes and delivers the agreement provided for in this Section 10 or which otherwise becomes bound by all the terms and provisions of this Agreement by operation of law.  In the event that any successor refuses to assume the obligations hereunder, the Company as hereinbefore defined shall remain fully responsible for all obligations hereunder.

11.Notices.  All notices, requests, demands and other communications hereunder shall be in writing and shall be given by hand delivery, electronic mail, facsimile, telecopy, overnight courier service, or by United States certified or registered mail, return receipt requested.  Each such notice, request, demand or other communication shall be effective (i) if delivered by hand or by overnight courier service, when delivered at the address specified in this Section 11; (ii) if given by electronic mail, facsimile or telecopy, when such electronic mail, facsimile or telecopy is transmitted to

-11-


the electronic mail address or facsimile or telecopy number specified in this Section 11 and confirmation is received if during normal business hours on a business day, and otherwise, on the next business day; and (iii) if given by certified or registered mail, three (3) days after the mailing thereof.  Notices shall be addressed to the parties as follows (or at such other address, email address or fax number as either party may from time to time specify in writing by giving notice as provided herein):

 

If to the Company:

STAAR Surgical Company
25651 Atlantic Ocean Drive
Lake Forest, California 92630
Attn:  Board of Directors

 

If to Executive:

Thomas Frinzi

 

209 Emerald Ave.

 

Balboa Island, CA 92662
Email: tomfrinzi@gmail.com

12.Indemnification.  The Company will indemnify Executive to the fullest extent permitted and required by the laws of the State of California.  

13.Dispute Resolution.  The parties agree that all disputes, claims or controversies between them and between Executive and the Company and its successor, including any dispute, claim or controversy arising from or otherwise in connection with this Agreement and/or Executive’s employment with the Company, will be resolved as follows:

(a)Prior to initiating any other proceeding, the complaining party will provide the other party with a written statement of the claim identifying any supporting witnesses or documents and the requested relief.  The responding party shall within forty-five (45) days furnish a statement of the relief, if any, that it is willing to provide, and identify supporting witnesses or documents.

(b)If the matter is not resolved by the exchange of statements of claim and statements of response as provided herein, within thirty (30) days from the responding party’s response, the parties shall submit the dispute to non-binding mediation, the cost of the mediator to be paid by the Company, before a mediator and/or service to be jointly selected by the parties.  Each party will bear his or its own attorney’s fees and witness fees.

(c)If the parties cannot agree on a mediator and/or if the matter is not otherwise resolved by mediation, any controversy or claim between Executive and the Company and any of its current or former directors, officers and employees, including any arising out of or relating to this Agreement or breach thereof, shall be settled by final and binding arbitration in Orange County, California by a single arbitrator pursuant to the Employment Dispute Rules of Judicial Arbitration and Mediation Services, Inc.

-12-


(“JAMS”), unless the parties to the dispute agree to another arbitration service or independent arbitrator.  The parties may conduct discovery to the extent permitted in a court of law pursuant to the California Code of Civil Procedure; the arbitrator will render an award together with a written opinion indicating the bases for such opinion; and the arbitrator will have full authority to award all remedies that would be available in court.  Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.  Each party shall bear its own attorney’s fees and costs, unless the claim is based on a statute that provides otherwise.  The Company will pay the arbitrator’s fees and any administrative charges of the arbitration service,

(d)EXECUTIVE AND THE COMPANY AGREE THAT THIS ARBITRATION PROCEDURE IS SUBJECT TO AND ENFORCEABLE UNDER THE FEDERAL ARBITRATION ACT (9 U.S.C. SECTIONS 1 ET SEQ.), AND WILL BE THE EXCLUSIVE MEANS OF REDRESS FOR ANY DISPUTES RELATING TO OR ARISING FROM EXECUTIVE’S EMPLOYMENT WITH THE COMPANY OR TERMINATION THEREFROM, INCLUDING DISPUTES OVER UNPAID WAGES, BREACH OF CONTRACT OR TORT, VIOLATION OF PUBLIC POLICY, RIGHTS PROVIDED BY FEDERAL, STATE OR LOCAL STATUTES, REGULATIONS, ORDINANCES, AND COMMON LAW, LAWS THAT PROHIBIT DISCRIMINATION BASED ON ANY PROTECTED CLASSIFICATION, AND ANY OTHER STATUTES OR LAWS RELATING TO AN EXECUTIVE’S RELATIONSHIP WITH THE COMPANY.  THE FOREGOING NOTWITHSTANDING, CLAIMS FOR WORKERS’ COMPENSATION BENEFITS OR UNEMPLOYMENT INSURANCE, OR ANY OTHER CLAIMS WHERE MANDATORY ARBITRATION IS PROHIBITED BY LAW, ARE NOT COVERED BY THIS ARBITRATION PROVISION.  THE PARTIES EXPRESSLY WAIVE THE RIGHT TO A JURY TRIAL, AND AGREE THAT THE ARBITRATOR’S AWARD SHALL BE FINAL AND BINDING ON BOTH PARTIES.  THIS ARBITRATION PROVISION IS TO BE CONSTRUED AS BROADLY AS IS PERMISSIBLE UNDER APPLICABLE LAW.

14.Representations.  Each person executing this Agreement hereby represents and warrants on behalf of himself and of the entity/individual on whose behalf he is executing the Agreement that he is authorized to represent and bind the entity/individual on whose behalf he is executing the Agreement.  Executive specifically represents and warrants to the Company that he reasonably believes (a) he is not under any contractual or other obligations that would prevent, limit or impair Executive’s performance of his obligations under this Agreement and (b) that entering into this Agreement will not result in a breach of any other agreement to which he is a party.

15.Amendments and Waivers.  No provisions of this Agreement may be modified, waived, or discharged except by a written document signed by Executive and a duly authorized Company officer.  Thus, for example, promotions, commendations, and/or bonuses shall not, by themselves, modify, amend, or extend this Agreement.  A waiver of any conditions or provisions of this Agreement in a given instance shall not be deemed a waiver of such conditions or provisions at any other time.

16.Taxes.  

-13-


(a)Withholdings.  The Company may withhold from any compensation and benefits payable under this Agreement all federal, state, city and other taxes or amounts as shall be determined by the Company to be required to be withheld pursuant to applicable laws, or governmental regulations or rulings.  Executive shall be solely responsible for the satisfaction of any taxes (including employment taxes imposed on employees and penalty taxes on nonqualified deferred compensation).  

(b)Section 280G.  

In the event that any payment or benefit received or to be received by Executive pursuant to this Agreement or under any other agreement, contract, award, arrangement, etc. (collectively, the “Payments”) would result in a “parachute payment” as described in Section 280G of the Internal Revenue Code of 1986, as amended (or any successor provision), notwithstanding the other provisions of this Agreement, or any other agreement, contract, award, arrangement, etc., such Payments shall not, in the aggregate, exceed the Reduced Amount (as defined below). The “Reduced Amount” shall be either (x) the largest portion of the Payments that would result in no portion of the Payments (after reduction) being subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”) or (y) the full amount of the Payments, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax, as determined in good faith by the Company’s independent auditors.  If any benefits must be cut back pursuant to this subsection (b), they shall be cut back in the following order: (A) cash payments; (B) cancellation of accelerated vesting of equity awards other than stock options (with the latest vesting reduced first), and (C) cancellation of accelerated vesting of stock options (with the latest vesting reduced first).  If an amount in excess of the Reduced Amount is paid to Executive, he shall repay the excess amount to the Company on demand, with interest at the rate provided for in Internal Revenue Code Section 1274(b)(2)(B) (or any successor provision).  The Company and Executive agree to cooperate with each other in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute penalties.  

 

(c)Section 409A Compliance.

(i)Section 409A Six-Month Delay Rule.  If any amounts that become due under Section 5 of this Agreement constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (or any successor provision), payment of such amounts shall not commence until Executive incurs a “separation from service” within the meaning of Treasury Regulation Section 1.409A-1(h). If, at the time of Executive’s separation from service, Executive is a “specified employee” (under Section 409A), any benefit as to

-14-


which Section 409A penalties could be assessed that becomes payable to Executive on account of his “separation from service” (including any amounts payable pursuant to the preceding sentence) will not be paid until after six months and one day after Executive’s separation from service (the “409A Suspension Period”).  Within fourteen (14) calendar days after the end of the 409A Suspension Period, Executive shall be paid a lump sum payment in cash equal to any payments delayed because of the preceding sentence, together with interest on them for the period of delay at a rate not less than the average prime interest rate published in the Wall Street Journal on any day chosen by the Company during that period. Thereafter, Executive shall receive any remaining benefits as if there had not been an earlier delay.

(ii)Interpretation.  This Agreement is intended to comply with or be exempt from Section 409A, and the Company shall have complete discretion to interpret and construe this Agreement and any associated documents in any manner that establishes an exemption from (or otherwise conforms them to) the requirements of Section 409A.  To the extent that any regulations or other guidance issued under Section 409A (after application of the previous sentence) would result Executive being subject to the payment of interest or any additional tax under Section 409A, the parties agree, to the extent reasonably possible, to amend this Agreement in order to avoid the imposition of any such interest or additional tax under Section 409A, which such amendment shall have the minimum economic effect necessary and be reasonably determined in good faith by Executive and the Company, provided it does not increase the overall expense to the Company in providing the benefits.

17.U.S. Citizenship and Immigration Services.  Executive agrees to timely file all documents required by the Department of Homeland Security to verify his identity and lawful employment in the United States.

18.Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute the same instrument.

-15-


19.Executive’s Acknowledgement.

EXECUTIVE ACKNOWLEDGES THAT ALL UNDERSTANDINGS AND AGREEMENTS BETWEEN THE COMPANY AND HE RELATING TO THE SUBJECTS COVERED IN THIS AGREEMENT ARE CONTAINED IN IT (INCLUDING THE AGREEMENTS SET FORTH AS EXHIBITS) AND THAT HE HAS ENTERED INTO THIS AGREEMENT VOLUNTARILY AND NOT IN RELIANCE ON ANY PROMISES OR REPRESENTATIONS BY THE COMPANY OTHER THAN THOSE CONTAINED IN THIS AGREEMENT.

 

Executive FURTHER ACKNOWLEDGES THAT HE HAS CAREFULLY READ THIS AGREEMENT (INCLUDING THE AGREEMENTS SET FORTH AS EXHIBITS), THAT HE UNDERSTANDS ALL OF SUCH AGREEMENTS, AND THAT HE HAS BEEN GIVEN THE OPPORTUNITY TO DISCUSS SUCH AGREEMENTS WITH HIS PRIVATE LEGAL COUNSEL AND HAS AVAILED HIMSELF OF THAT OPPORTUNITY TO THE EXTENT HE WISHED TO DO SO.  EXECUTIVE UNDERSTANDS THAT THE DISPUTE RESOLUTION PROVISIONS OF THIS AGREEMENT GIVE UP THE RIGHT TO A JURY TRIAL ON MATTERS COVERED BY THEM.

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

Thomas G. Frinzi

/s/

 

 

 

STAAR Surgical Company

 

By:  /s/

 

Name:  

 

Title:  

 

-16-


Exhibit 10.1

 

Exhibit A

 

 

FORM OF SEPARATION AGREEMENT AND GENERAL RELEASE

 

SEPARATION AGREEMENT AND GENERAL RELEASE

This Separation Agreement and General Release (this “Agreement”) is hereby entered into by and between Thomas G. Frinzi, an individual (“Executive”), and STAAR Surgical Company, a Delaware corporation, on behalf of itself and any and all affiliated entities (collectively, the “Company”).

Recitals

A.Executive has been employed by the Company pursuant to an employment agreement by and between the Company and Executive effective as of [date] (the “Employment Agreement”), and currently is serving as Chief Executive Officer;

 

B.Executive’s employment with the Company and any of its parents, direct or indirect subsidiaries, affiliates, divisions, or related entities (collectively referred to herein as the “Company and its Related Entities”) will be ended on the terms and conditions set forth in this Agreement.  

Agreement

In consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereby agree as follows:

1.Effective Date. Except as otherwise provided herein, this Agreement shall be effective on the eighth day after it has been executed by both of the parties (the “Effective Date”).

2.End of Employment. Executive’s employment with the Company and its Related Entities has ended or will end, effective as of ___________ Pacific Time, on _________________ (the “Termination Date”).

3.Continuation of Benefits After the Termination Date. Except as expressly provided in this Agreement or in the plan documents governing the Company’s employee benefit plans, after the Termination Date, Executive will no longer be eligible for, receive, accrue, or participate in any other benefits or benefit plans provided by the Company and its Related Entities, including, without limitation, medical, dental and life insurance benefits, and the Company’s 401(k) retirement plan; provided, however, that

 


Exhibit 10.1

nothing in this Agreement shall waive Executive’s right to any vested benefits, including vested amounts in the Company’s 401(k) retirement plan, which amounts shall be handled as provided in the plan.

4.Payments Upon Termination.  Executive will be entitled to receive payment of the following:  (i) all earned but unpaid compensation (including accrued unpaid vacation) through the effective date of termination, payable on or before the termination date; and (ii) reimbursement, made in accordance with Section 4(e) of the Employment Agreement, of any monies advanced or incurred by Executive in connection with his employment for reasonable and necessary Company-related expenses incurred on or before the Termination Date.  The provisions of this Agreement shall not waive or terminate any rights to compensation or vested benefits as required by law, or to indemnification Executive may have under the Company’s Certificate of Incorporation, Bylaws or separate indemnification agreement, as applicable.  

5.Insurance. Executive will be provided continued coverage under the Company’s medical, dental and vision insurance benefit plans through the Termination Date, and thereafter, the Company shall reimburse Executive for the cost of continuation of such group insurance coverage for himself and his eligible dependents under the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1986 (“COBRA”) for eighteen (18) months after the Termination Date.  

(a)Severance Payment [and Change in Control Benefits]. In return for Executive’s promises in this Agreement, the Company will provide Executive with a severance payment in an amount equal to the Base Salary Executive would have earned over the next eighteen (18) months (less necessary withholdings and authorized deductions) at his then current Base Salary rate (the “Severance Payment”) The Base salary shall be in an amount no less than the Executive Base Salary set forth in paragraph 4 (a) of Executive’s Employment Agreement dated ________. [for Change in Control resignation or termination, add: plus an amount equal to Executive’s bonus, if any, for the year prior to the end of his employment and an amount equal to Executive’s target bonus for the year in which her employment ends], which will be paid in equal monthly installments over the eighteen (18) months following the Termination Date (the “Severance Period”) [OR, at the option of the Board: in a lump sum within two business days after the Effective Date], subject to Section 21??, below.

6.Effect of Revocation or Subsequent Employment.

(a)If Executive properly revokes this Agreement in accordance with Section 14 below, Executive shall not be entitled to receive the payments and benefits under Sections 5 and 6, above, except that Executive’s rights under COBRA will continue.

(b)The Company’s obligation to reimburse the premiums for Executive’s continuation insurance coverage will be extinguished as of the date Executive’s coverage begins under the group health plan of any new employer.  Executive shall promptly provide written notice to the Company after he learns he will be eligible for such insurance coverage.  If Executive violates the restrictions in Section 18, below, the

-1-


Companys obligation to pay premiums for insurance under COBRA or otherwise will be immediately extinguished, and the other remedies specified in Section 18, below, shall apply.  

7.Acknowledgement of Total Compensation and Indebtedness. Executive acknowledges and agrees that the cash payments under Sections 4, 5 and 6 of this Agreement extinguish any and all obligations for monies, or other compensation or benefits that Executive claims or could claim to have earned or claims or could claim is owed to her as a result of his employment by the Company and its Related Entities through the Termination Date, under the Employment Agreement or otherwise.  Notwithstanding the foregoing, the parties acknowledge and agree that the provisions of this Section 10 shall not terminate any rights Executive has under Section 3 or to other payments Executive may have, and to any indemnification Executive may have under the Company’s Certificate of Incorporation, Bylaws or separate indemnification agreement, as applicable.

8.Status of Related Agreements and Future Employment.

(a)Agreements Between Executive and the Company. [Agreements to be scheduled at time].  

(b)Employment Agreement. The parties agree that the Employment Agreement shall be terminated as of the Termination Date. Notwithstanding the termination of the Employment Agreement, the parties hereto acknowledge that certain rights and obligations set forth in the Employment Agreement extend beyond the Termination Date.  In the event that any provision of this Agreement conflicts with Section 6 of the Employment Agreement, the terms and provisions of the section(s) providing the greatest protection to the Company and its Related Entities shall control.

9.Release by Executive.

(a)Except for any obligations or covenants of the Company pursuant to this Agreement and as otherwise expressly provided in this Agreement, Executive, for himself and his heirs, executors, administrators, assigns, successors and agents (collectively, the “Executive’s Affiliates”) hereby fully and without limitation releases and forever discharges the Company and its Related Entities, and each of their respective agents, representatives, shareholders, owners, officers, directors, employees, consultants, attorneys, auditors, accountants, investigators, affiliates, successors and assigns (collectively, the “Company Releasees”), both individually and collectively, from any and all rights, claims, demands, liabilities, actions, causes of action, damages, losses, costs, expenses and compensation, of whatever nature whatsoever, known or unknown, fixed or contingent, which Executive or any of Executive’s Affiliates has or may have or may claim to have against the Company Releasees by reason of any matter, cause, or thing whatsoever, from the beginning of time to the Effective Date (“Claims”), arising out of, based upon, or relating to his employment or the termination of his employment with the Company and its Related Entities and/or hisr service as an officer of any of the

-2-


Company Releasees, any agreement or compensation arrangement between Executive and any of the Company Releasees, to the maximum extent permitted by law.  

(b)Executive specifically and expressly releases any Claims arising out of or based on: the California Fair Employment and Housing Act, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the National Labor Relations Act and the Equal Pay Act, as the same may be amended from time to time; the California common law on fraud, misrepresentation, negligence, defamation, infliction of emotional distress or other tort, breach of contract or covenant, violation of public policy or wrongful termination; state or federal wage and hour laws, and other provisions of the California Labor Code, to the extent these may be released herein as a matter of law; or any other state or federal law, rule, or regulation dealing with the employment relationship.

(c)Nothing contained in this Section 10 or any other provision of this Agreement shall release or waive any right that Executive has to indemnification and/or reimbursement of expenses by the Company and its Related Entities with respect to which Executive may be eligible as provided in California Labor Code section 2802, the Company’s and its Related Entities’ Certificates of Incorporation, Bylaws and any applicable directors and officers, errors & omissions, umbrella or general liability insurance policies, any indemnification agreements, including the Employment Agreement; or any other applicable source, nor prevent Executive from cooperating in an investigation of the Company by the Equal Employment Opportunity Commission (“EEOC”).  

10.Waiver of Civil Code Section 1542.

(a)Executive understands and agrees that the release provided herein extends to all Claims released above whether known or unknown, suspected or unsuspected, which may be released as a matter of law. Executive expressly waives and relinquishes any and all rights he may have under California Civil Code section 1542, which provides as follows:

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

(b)Executive expressly waives and releases any rights and benefits which he has or may have under any similar law or rule of any other jurisdiction. It is the intention of each party through this Agreement to fully, finally and forever settle and release the Claims as set forth above. In furtherance of such intention, the release herein given shall be and remain in effect as a full and complete release of such matters notwithstanding the discovery of any additional Claims or facts relating thereto.

-3-


11.[If Executive is age 40 or over on Termination Date] Release of Federal Age Discrimination Claims by Executive. Executive hereby knowingly and voluntarily waives and releases all rights and claims, known or unknown, arising under the Age Discrimination In Employment Act of 1967, as amended, which he might otherwise have had against the Company or any of the Company Releasees regarding any actions which occurred prior to the date that Executive signed this Agreement, except that Executive is not prevented from cooperating in an investigation by the EEOC or from filing an EEOC charge other than for personal relief.

12.[Intentionally omitted].

13.Review and Revocation Rights. Executive hereby is advised of the following:

(a)Executive has the right to consult with an attorney before signing this Agreement and is encouraged by the Company to do so;

(b)Executive has twenty-one (21) days from his receipt of this Agreement to consider it; and

(c)Executive has seven (7) days after signing this Agreement to revoke this Agreement, and this Agreement will not be effective until that revocation period has expired without revocation. Executive agrees that in order to exercise her right to revoke this Agreement within such seven (7) day period, he must do so in a signed writing delivered to the Company’s Board of Directors of the Company (“Board”) before the close of business on the seventh calendar day after he signs this Agreement.

14.Confidentiality of Agreement. After the execution of this Agreement by Executive, neither Executive, his attorney, nor any person acting by, through, under or in concert with them, shall disclose any of the terms of or amount paid under this Agreement (other than to state that the Company has filed this Agreement and/or agreements related thereto as public documents) or the negotiation thereof to any individual or entity; provided, however, that the foregoing shall not prevent such disclosures by Executive to his attorney, tax advisors and/or immediate family members, or as may be required by law.

15.No Filings. Executive represents that he has not filed any waivable lawsuits, claims, charges or complaints, which are pending as of the date hereof, against the Company Releasees with any local, state or federal agency or court from the beginning of time to the date of execution of this Agreement and that, if any such agency or court ever assumes jurisdiction over any such lawsuit, claim, charge or complaint and/or purports to bring any legal proceeding, in whole or in part, on behalf of Executive based upon events occurring prior to the execution of this Agreement, Executive will request such agency or court to withdraw from and/or to dismiss the lawsuit, claim, charge or complaint with prejudice.

16.Confidential and Proprietary Information. Executive acknowledges that certain information, observations and data obtained by him during the course of or

-4-


related to his employment with the Company and its Related Entities (including, without limitation, projection programs, business plans, business matrix programs (i.e., measurement of business), strategic financial projections, certain financial information, shareholder information, product design information, marketing plans or proposals, personnel information, customer lists and other customer information) are the sole property of the Company and its Related Entities and constitute Proprietary Information as defined in Section 6 of the Employment Agreement.  Executive represents and warrants that he has returned all files, customer lists, financial information and other property of the Company and its Related Entities that were in Executive’s possession or control without retaining copies thereof.  Executive further represents and warrants that he does not have in his possession or control any files, customer lists, financial information or other property of the Company and its Related Entities. In addition to his promises in Section 6 of the Employment Agreement, Executive agrees that he will not disclose to any person or use any such information, observations or data without the written consent of the Board.  If Executive is served with a deposition subpoena or other legal process calling for the disclosure of such information, or if he is contacted by any third person requesting such information, he will notify the Board as soon as is reasonably practicable after receiving  notice and will reasonably cooperate with the Company and its Related Entities in minimizing the disclosure thereof; provided, that nothing in this Agreement will affect Executive’s obligations to testify truthfully in response to any subpoena or other legally required discovery proceeding. Further if any such cooperation requires Executive’s participation in any legal proceeding, Company will reimburse Executive for his time commensurate with his hourly rate at the time he was employed with Company. In the event Executive requires legal representation in connection with such cooperation, Company will pay for Executives legal fees.

17.Prohibited Activities.

(a)[Intentionally omitted].  

(b)Non-Solicitation of Employees.  Executive recognizes the substantial expenditure of time and effort which the Company devotes to the recruitment, hiring, orientation, training and retention of its employees.  Accordingly, Executive agrees that, for a period beginning on the Effective Date and ending twelve (12) months after termination of Executive’s employment with the Company, regardless of the reason for such termination, Executive shall not use any Proprietary Information, directly or indirectly, for himself or on behalf of any other person or entity, solicit, offer employment to, hire or otherwise retain the services of any employee of the Company in a position classified as exempt from overtime pay requirements.  For purposes of the foregoing, “employee of the Company” shall include any person who was an employee of the Company at any time within six (6) months prior to the prohibited conduct.  

(c)Scope of Restrictions. Executive agrees that the restrictions in Sections 18 (a) and (b), above, are reasonable and necessary to protect the Company’s trade secrets.  To the extent that any of the provisions in this Section 18 are held to be overly broad or otherwise unenforceable at the time enforcement is sought, Executive agrees that the provision shall be reformed and enforced to the greatest extent permissible by law.  

-5-


Executive further agrees that if any portion of this Section 18 is held to be unenforceable, that the remaining provisions of it shall be enforced as written.

18.Remedies. Executive acknowledges that any misuse of Proprietary Information belonging to the Company and its Related Entities, or any violation of Section 6 of the Employment Agreement, and any violation of Sections 15, 17 and 18 of this Agreement, will result in irreparable harm to the Company and its Related Entities, and therefore, the Company and its Related Entities shall, in addition to any other remedies, be entitled to immediate injunctive relief. To the extent there is any conflict between Section 6 of the Employment Agreement and this Section 19, the provision providing the greatest protection to the Company and its Related Entities shall control. In addition, in the event of a breach of any provision of this Agreement by Executive, including Sections 15, 17 and 18, Executive shall forfeit, and the Company and its Related Entities may cease paying, any unpaid installments of the Severance Payment and providing any further medical insurance benefits under Sections 5 and 6, above.  

19.Cooperation Clause.

(a)To facilitate the orderly conduct of the Company and its Related Entities’ businesses, for the Severance Period, Executive agrees to cooperate, at no charge, with the Company and its Related Entities’ reasonable requests for information or assistance related to the time of his employment.

(b)For the Severance Period, Executive agrees to cooperate, at no charge, with the Company’s and its Related Entities’ and its or their counsel’s reasonable requests for information or assistance related to (i) any investigations (including internal investigations) and audits of the Company’s and its Related Entities’ management’s current and past conduct and business and accounting practices and (ii) the Company’s and its Related Entities’ defense of, or other participation in, any administrative, judicial, or other proceeding arising from any charge, complaint or other action which has been or may be filed relating to the period during which Executive was employed by the Company and its Related Entities.   The Company will promptly reimburse Executive for his reasonable, customary and documented out-of-pocket business expenses in connection with the performance of her duties under this Section 20.  Except as required by law or authorized in advance by the Board of Directors of the Company, Executive will not communicate, directly or indirectly, with any third party other than Executive’s legal counsel or his own legal counsel, including any person or representative of any group of people or entity who is suing or has indicated that a legal action against the Company and its Related Entities or any of their directors or officers is being contemplated, concerning the management or governance of the Company and its Related Entities, the operations of the Company and its Related Entities, the legal positions taken by the Company and its Related Entities, or the financial status of the Company and its Related Entities. If asked about any such individuals or matters, Executive shall say: “I have no comment,” and shall direct the inquirer to the Company. Executive acknowledges that any violation of this Section 20 will result in irreparable harm to the Company and its Related Entities and will entitle the Company and its Related Entities to injunctive relief.

-6-


20.No Future Employment. Executive understands that his employment with the Company and its Related Entities will irrevocably end as of the Termination Date and will not be resumed at any time in the future. Executive agrees that he will not apply for, seek or accept employment by the Company and its Related Entities at any time, unless invited to do so by the Company and its Related Entities.

21.Tax Issues.  The parties agree that the payments and benefits provided under this Agreement, and all other contracts, arrangements or programs that apply to him, shall be subject to Section 16 of the Employment Agreement.  

22.Non-disparagement.  Executive agrees not to criticize, denigrate, or otherwise disparage the Company and its Related Entities, or any of their directors, officers, products, processes, experiments, policies, practices, standards of business conduct, or areas or techniques of research.  The Company agrees not to authorize or condone denigrating or disparaging statements about Executive to any third party, including by press release or other formally released announcement.  Factually accurate statements in legal or public filings shall not violate this provision.  In addition, nothing in this Section 23 shall prohibit Executive or the Company or the Board, or any of their employees or members from complying with any lawful subpoena or court order or taking any other actions affirmatively authorized by law.

23.Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without giving effect to principles of conflict of laws.

24.Dispute Resolution. The parties hereby agree that all disputes, claims or controversies arising from or otherwise in connection with this Agreement (except for injunctive relief sought by either party) between them and between Executive and any of the Company’s affiliated entities and the successor of all such entities, and any director, shareholder or employee of the Company will be resolved in accordance with Section 13 of the Employment Agreement, except for its attorneys’ fee provision.

25.Attorneys’ Fees. Except as otherwise provided herein, in any action, litigation or proceeding between the parties arising out of or in relation to this Agreement, including any purported breach of this Agreement, the prevailing party shall be entitled to an award of its costs and expenses, including reasonable attorneys’ fees.

26.Non-Admission of Liability. The parties understand and agree that neither the payment of any sum of money nor the execution of this Agreement by the parties will constitute or be construed as an admission of any wrongdoing or liability whatsoever by any party.

27.Severability. If any one or more of the provisions contained herein (or parts thereof), or the application thereof in any circumstances, is held invalid, illegal or unenforceable in any respect for any reason, the validity and enforceability of any such provision in every other respect and of the remaining provisions hereof will not be in any

-7-


way impaired or affected, it being intended that all of the rights and privileges shall be enforceable to the fullest extent permitted by law.

28.Entire Agreement. This Agreement represents the sole and entire agreement among the parties and, except as expressly stated herein, supersedes all prior agreements, negotiations and discussions among the parties with respect to the subject matters contained herein.

29.Waiver. No waiver by any party hereto at any time of any breach of, or compliance with, any condition or provision of this Agreement to be performed by any other party hereto may be deemed a waiver of similar or dissimilar provisions or conditions at the same time or at any prior or subsequent time.

30.Amendment. This Agreement may be modified or amended only if such modification or amendment is agreed to in writing and signed by duly authorized representatives of the parties hereto, which writing expressly states the intent of the parties to modify this Agreement.

31.Counterparts. This Agreement may be executed in counterparts, each of which will be deemed to be an original as against any party that has signed it, but both of which together will constitute one and the same instrument.

32.Assignment. This Agreement inures to the benefit of and is binding upon the Company and its successors and assigns, but Executive’s rights under this Agreement are not assignable, except to his estate.

33.Notice. All notices, requests, demands, claims and other communications hereunder shall be in writing and shall be deemed to have been duly given (a) if personally delivered or delivered by overnight courier; (b) if sent by electronic mail, telecopy or facsimile (except for legal process); or (c) if mailed by overnight or by first class, United States certified or registered mail, postage prepaid, return receipt requested, and properly addressed as follows:

If to the Company:STAAR Surgical Company

25651 Atlantic Ocean Drive

Lake Forest, California 92630

Attn: Board of Directors

Fax No. [insert]

 

If to Executive:  [name]

                                 [address]

 

Email:
Fax No:

-8-


Such addresses may be changed, from time to time, by means of a notice given in the manner provided above. Notice will conclusively be deemed to have been given when personally delivered (including, but not limited to, by messenger or courier); or if given by mail, on the third business day after being sent by first class, United States certified or registered mail; or if given by Federal Express or other similar overnight service, on the date of delivery; or if given by electronic mail, telecopy or facsimile machine during normal business hours on a business day, when confirmation of transmission is indicated by the sender’s machine; or if given by electronic mail, telecopy or facsimile machine at any time other than during normal business hours on a business day, the first business day following when confirmation of transmission is indicated by the sender’s machine. Unless otherwise agreed, notices, requests, demands and other communications delivered to legal counsel of any party hereto, whether or not such counsel shall consist of in-house or outside counsel, shall not constitute duly given notice to any party hereto.

34.Miscellaneous Provisions.

(a)The parties represent that they have read this Agreement and fully understand all of its terms; that they have conferred with their attorneys, or have knowingly and voluntarily chosen not to confer with their attorneys about this Agreement; that they have executed this Agreement without coercion or duress of any kind; and that they understand any rights that they have or may have, and they are signing this Agreement with full knowledge of any such rights.

(b)Both parties have participated in the drafting of this Agreement with the assistance of counsel to the extent they desired. The language in all parts of this Agreement must be in all cases construed simply according to its fair meaning and not strictly for or against any party. Whenever the context requires, all words used in the singular must be construed to have been used in the plural, and vice versa, and each gender must include any other gender. The captions of the Sections of this Agreement are for convenience only and must not affect the construction or interpretation of any of the provision herein.

(c)Each provision of this Agreement to be performed by a party hereto is both a covenant and condition, and is a material consideration for the other party’s performance hereunder, and any breach thereof by the party will be a material default hereunder. All rights, remedies, undertakings, obligations, options, covenants, conditions and agreements contained in this Agreement are cumulative and no one of them is exclusive of any other. Time is of the essence in the performance of this Agreement.

(d)Each party acknowledges that no representation, statement or promise made by any other party, or by the agent or attorney of any other party, except for those in this Agreement, has been relied on by her or it in entering into this Agreement.

(e)Unless expressly set forth otherwise, all references herein to a “day” are deemed to be a reference to a calendar day. All references to “business day” mean any day of the year other than a Saturday, Sunday or a public or bank holiday in Orange

-9-


County, California. Unless expressly stated otherwise, cross-references herein refer to provisions within this Agreement and are not references to any other document.

(f)Each party to this Agreement will cooperate fully in the execution of any and all other documents and in the completion of any additional actions that may be necessary or appropriate to give full force and effect to the terms and intent of this Agreement.

EACH OF THE PARTIES ACKNOWLEDGES THAT HE/IT HAS READ THIS AGREEMENT, UNDERSTANDS IT AND IS VOLUNTARILY ENTERING INTO IT, AND THAT IT INCLUDES A WAIVER OF THE RIGHT TO A TRIAL BY JURY, AND, WITH RESPECT TO EXECUTIVE, HE UNDERSTANDS THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.

[SIGNATURES ON NEXT PAGE]


-10-


IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the day and year first above written.

EXECUTIVE:

 

 

 

 

Thomas G. Frinzi

 

 

 

COMPANY:

 

STAAR Surgical Company

 

 

 

By:  

    

 

 

Name:

 

 

 

Title:  

 

 

-11-

EX-10.2 3 staa-ex102_6.htm EX-10.2 staa-ex102_6.htm

Exhibit 10.2

CONSULTING AGREEMENT

This Consulting Agreement (“Agreement”) is made as of January 1, 2023, by and between Caren Mason, an independent consultant (“the Consultant”), and STAAR Surgical Company, a Delaware corporation, whose address is 25651 Atlantic Ocean Drive, Lake Forest, California 92630 (“the Company”), in reference to the following:

RECITALS

A.  The Company is in the business of manufacturing and selling medical products used for surgical implantation in the human eye.

B. The Consultant is the former Chief Executive Officer of the Company with expertise is a wide range of leadership, strategic, and operational matters regarding the Company.  

C. The Company wishes to retain the Consultant, and the Consultant wishes to be retained by the Company.

NOW, THEREFORE, in consideration of the premises stated above, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Consultant agree as follows:

AGREEMENT

1.Term.  The Company retains the Consultant and the Consultant accepts this appointment with the Company for a period beginning on January 1, 2023 (the “Commencement Date”) and ending December 29, 2023.

2.Duties of the Consultant.  The Consultant agrees to perform the services described in Exhibit A to this Agreement.  The Consultant will determine the method, details and means of performing the services.  

3.Compensation.  The Company shall pay to the Consultant, as compensation for the services performed pursuant to this Agreement, the amount of one hundred thousand dollars per month ($100,000.00), to be paid on the last day of each month during the term of this agreement after the performance of the services to be performed in that monthly period.  

4.Nondisclosure and Noncompetition.  

4.1.Access to Confidential Information.  The Consultant acknowledges that during the term of the business relationship between the Consultant and the Company, the Consultant will have access to, view, make use of and add value to confidential proprietary information of the Company, which includes, without limitation, trade secrets, systems, designs, methods, formulae, specifications, proprietary techniques, documentation, manuals, files, records, computer software programs, white papers, other confidential reports and communications and lists of and information relating to suppliers, customers and prospects, whether provided by the Company or developed by the Consultant (“Confidential Information”).  The Consultant further acknowledges that any information and materials

-1-


received by the Company from third parties in confidence (including materials so received by the Consultant on behalf of the Company) shall be included in the definition of Confidential Information.  

4.2.Nondisclosure of Confidential Information.  The Consultant agrees to hold all Confidential Information in strict confidence, and agrees not to directly or indirectly disclose, divulge, reveal, report, publish or transfer, for any purpose whatsoever, any Confidential Information to any person or entity.  The Consultant acknowledges that the Company holds all right, title, and interest in and to all tangible and intangible incidents of the Confidential Information, including, without limitation, all trade secrets, copyrights, patent rights and derivative works pertaining thereto, and that this agreement conveys to the Consultant only a limited right to use the Confidential Information in the course of performing this Agreement.  Such right is fully revocable in accordance with the provisions of this Agreement.  The Consultant further agrees that, except for such right of use, it shall not assert any right, title, or interest in or to the Confidential Information.  The Consultant agrees to return all Confidential Information in the Consultant's possession or under the Consultant's control at the request of the Company or, in the absence of such a request, upon the termination of this Agreement.

4.3.No Unfair Use by the Consultant.  The Consultant agrees that the Consultant shall not use Confidential Information in any way or at any time except as required in the course of the Consultant’s business relationship with the Company, nor will the Consultant appropriate Confidential Information for the Consultant’s own use or the use of any other party.  The Consultant agrees that any use, appropriation or disclosure of Confidential Information not in accordance with this Agreement constitutes unfair competition.  The Consultant promises and agrees not to engage in any unfair competition with the Company.  

4.4.Right of Injunction.  As any breach by the Consultant of its covenants and agreements in this section may cause irreparable injury to the Company that cannot be redressed by the payment of monies, the Company shall be entitled to enjoin any such threatened or continuing violation.  

4.5.Excluded Information.  “Confidential Information” shall not include information which is or becomes publicly available without breach of (i) this Agreement, (ii) any other agreement or instrument to which the Company is a party or a beneficiary or (iii) any duty owed to the Company by the Consultant or any third party; provided, however, that the Consultant hereby acknowledges and agrees that if the Consultant shall seek to disclose, divulge, reveal, report, publish, transfer or use any Confidential Information to any third party, the Consultant shall bear the burden of proving that any such information shall have become publicly available without any such breach.  Disclosure of Confidential Information shall not be prohibited if such disclosure is directly pursuant to a valid and existing order of a court or other governmental body or agency; provided, however, that (i) the Consultant shall first have given prompt notice to the Company of any such possible or prospective order (or proceeding pursuant to which any such order may result) and (ii) the Company shall have been afforded a reasonable opportunity to prevent or limit any such disclosure.  

-2-


5.Ownership of Information.  

5.1.Property Belonging to the Company.  The Consultant agrees that all right, title and interest in any findings, reports, inventions, writings, disclosures, discoveries, computer code, developments and improvements written, invented, made or conceived by the Consultant and relating to implantable devices, instruments or equipment for ophthalmic surgery or related procedures (“inventions”) in the course of or arising out this Agreement and with the Company’s equipment, supplies, facilities or confidential proprietary information shall be the sole and exclusive property of the Company and shall be work made for hire.  The Consultant agrees to disclose all such inventions to the Company.  

5.2.Further Acts.  The Consultant agrees that, both during and after the Consultant's engagement by the Company, upon the request of the Company and without further compensation, but at no expense to the Consultant, the Consultant shall execute any instruments and to do all other things reasonably requested by the Company, including the giving of testimony, that in the opinion of the Company, its successors or assigns, may be necessary or desirable in order to obtain, sustain, reissue and renew, and in order to enforce, perfect, record and maintain the Company’s rights to its inventions, including without limitation patent applications and United States and foreign patents on the Company’s inventions, and copyright registrations on the Company’s inventions.  

6.Termination Without Cause.  

6.1.Termination Due to Death.  This Agreement shall be terminated upon the death of the Consultant and no further payments shall be made pursuant to its terms.

6.2.Termination Due to Disability.  The Company reserves the right to terminate this Agreement immediately after the Consultant suffers any physical or mental disability that, in the Company’s sole determination, would prevent the performance of the Consultant’s duties under this Agreement.  A termination pursuant to this section shall be effected by giving ten days’ written notice of termination to the Consultant.

6.3.Termination Not For Cause.  Termination of this Agreement under this Section 6 shall not be considered “for cause.”

7.Termination for Cause.  

7.1.Termination for Cause.  The Company reserves the right to immediately terminate this Agreement if the Consultant breaches this Agreement or habitually neglects the duties that he or she is required to perform hereunder, or if he commits acts of dishonesty, fraud, or misrepresentation, misuses or misappropriates Confidential Information, or engages in unfair competition with the Company as contemplated by Section 4 above.  The Company reserves the right to immediately terminate this Agreement if the Consultant fails to promptly and faithfully comply with all present and future policies, requirements, directions, requests and rules and regulations of the Company or fails to conform to all laws and regulations or commits any act or becomes involved in any situation or occurrence tending to bring the Company into public scandal or ridicule or which will reflect unfavorably on the reputation of the Company.

-3-


7.2.Notice of Termination/No Election of Remedies.  If the Company terminates this Agreement pursuant to Section 7.1 above, the Company shall give written notice of termination to the Consultant without prejudice to any other remedy to which the Company may be entitled, either at law or in equity, under this Agreement.

7.3.Termination For Cause.  Termination of this Agreement under this section shall be considered termination “for cause.”

8.Termination by Notice.  With the exception of the obligations set forth in Section 10, either party may terminate this Agreement upon thirty days’ written notice to the other party.  

9.Survival of Obligations.  The Consultant’s obligations under Sections 4, 5, 15 and 16 represent a continuing obligation of the Consultant and shall survive any termination or expiration of this Agreement.  

10.Status of the Consultant.  The Consultant understands and agrees that she is not an employee of the Company and that she shall not be entitled to receive employee benefits from the Company, including, but not limited to, sick leave, vacation, retirement, death benefits, an automobile, stock in the Company and/or participation in profits earned by the Company.  The Consultant shall be responsible for providing, at the Consultant’s expense and in the Consultant’s name, disability, worker’s compensation or other insurance as well as licenses and permits usual or necessary for conducting the services hereunder.  Furthermore, the Consultant shall pay, when and as due, any and all taxes incurred as a result of the Consultant’s compensation hereunder, including estimated taxes, and shall provide the Company with proof of said payments, upon demand.  The Consultant hereby indemnifies the Company for any claims, losses, costs, fees, liabilities, damages or injuries suffered by the Company arising out of the Consultant’s breach of this section.

11.Representations by the Consultant.  The Consultant represents that the Consultant has the qualifications and ability to perform the services in a professional manner, without the advice, control, or supervision of the Company.  

12.Business Expenses.  The Company shall reimburse the Consultant for all reasonable travel, supplies, long-distance telephone and business expenses incurred by the Consultant during the course of this Agreement, provided that each such expenditure qualifies as a proper deduction on the Company’s federal and state income tax return.  Each such expenditure shall be reimbursable only if the Consultant furnishes to the Company adequate records and other documentary evidence required by federal and state statutes and regulations issued by the appropriate taxing authorities for the substantiation of that expenditure as an income tax deduction.  The Consultant may not incur any single business expense in an amount exceeding $1000.00 without the express prior written consent of the Company.  The Company shall, in its sole discretion, reimburse the Consultant or not, for any business expense which exceeds such amount and which is incurred by the Consultant without the prior written consent of the Company.

-4-


13.Notices.  Unless otherwise specifically provided in this Agreement, all notices or other communications (collectively and severally calledNotices) required or permitted to be given under this Agreement, shall be in writing, and shall be given by: (A) personal delivery (which form of Notice shall be deemed to have been given upon delivery), (B) by telegraph or by private airborne/overnight delivery service (which forms of Notice shall be deemed to have been given upon confirmed delivery by the delivery agency), or (C) by electronic mail or facsimile or telephonic transmission, provided the receiving party has a compatible device or confirms receipt thereof (which forms of Notice shall be deemed delivered upon confirmed transmission or confirmation of receipt).  Notices shall be addressed to the address set forth in the introductory section of this Agreement, or to such other address as the receiving party shall have specified most recently by like Notice, with a copy to the other party.

14.Choice of Law and Venue.  This Agreement shall be governed according to the laws of the state of California.  Venue for any legal or equitable action between the Company and the Consultant which relates to this Agreement shall be in the courts of the State of California in the County of Los Angeles and the Central District of California of the United States District Court.  

15.Indemnification.  The Consultant hereby agrees to indemnify, defend and hold harmless the Company, and the Company’s officers, directors, and shareholders from and against any and all claims, demands, losses, costs, expenses, obligations, liabilities, damages, recoveries, and deficiencies, including, without limitation, interest, penalties, and reasonable attorney fees and costs, that the Company may incur or suffer and that arise, result from, or are related to any breach or failure of the Consultant to perform any of the representations, warranties and agreements contained in this Agreement.

16.Entire Agreement.  This Agreement supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to the services to be rendered by the Consultant to the Company, and contains all of the covenants and agreements between the parties with respect to the services to be rendered by the Consultant to the Company in any manner whatsoever. The parties agree that Consultant’s Employment Agreement dated March 1, 2015 is terminated, effective December 31, 2022.  Each party to this agreement acknowledges that no representations, inducements, promises, or agreements, orally or otherwise, have been made by any party, or anyone acting on behalf of any party, that are not embodied herein, and that no other agreement, statement, or promise not contained in this Agreement shall be valid or binding on either party.

17.Independent Contractor.  The Consultant shall at all times be an independent contractor hereunder, and not a co-venturer, agent, employee or representative of the Company, and no act, action or omission to act of the Consultant shall in any way be binding upon or obligate the Company.  No change in the Consultant's duties as a consultant of the Company shall result in, or be deemed to be, a modification of the terms of this Agreement.  The Company shall not be treated as an employee for federal tax purposes.  The Consultant hereby represents and warrants to the Company that the Consultant is an independent contractor for federal, state and local tax purposes.  Further, the Consultant hereby covenants and agrees to pay any and all federal, state and local taxes required by law to be paid by an independent contractor, including, without limitation, any taxes imposed by the Self Employment Contribution Act.

-5-


18.Arbitration.  The parties hereby agree that all controversies, claims and matters of difference shall be resolved by binding arbitration before the American Arbitration Association (the "AAA") located in Los Angeles County, California according to the rules and practices of the AAA from time-to-time in force; provided however that the parties hereto reserve their rights to seek and obtain injunctive or other equitable relief from a court of competent jurisdiction, without waiving the right to compel such arbitration pursuant to this section.  The arbitrator shall apply California law in rendering a decision.

19.Severability.  If any term or provision of this Agreement or the application thereof to any person or circumstance shall, to any extent, be determined to be invalid, illegal or unenforceable under present or future laws effective during the term of this Agreement, then and, in that event: (A) the performance of the offending term or provision (but only to the extent its application is invalid, illegal or unenforceable) shall be excused as if it had never been incorporated into this Agreement, and, in lieu of such excused provision, there shall be added a provision as similar in terms and amount to such excused provision as may be possible and be legal, valid and enforceable, and (B) the remaining part of this Agreement (including the application of the offending term or provision to persons or circumstances other than those as to which it is held invalid, illegal or unenforceable) shall not be affected thereby and shall continue in full force and effect to the fullest extent provided by law.  

20.Amendment or Waiver.  No amendment to this Agreement shall be valid unless in writing and signed by both parties hereto. No waiver of any provision of this Agreement shall be valid unless the same is in writing and signed by the party against whom such waiver is sought to be enforced; moreover, no valid waiver of any provision of this Agreement at any time shall be deemed a waiver of any other provision of this Agreement at such time or shall be deemed a valid waiver of such provision at any other time.  

21.Preparation of Agreement.  It is acknowledged by each party that such party either had separate and independent advice of counsel or the opportunity to avail itself or himself of same.  In light of these facts it is acknowledged that no party shall be construed to be solely responsible for the drafting hereof, and therefore any ambiguity shall not be construed against any party as the alleged draftsman of this Agreement.

22.Data Privacy.  The Company and Consultant each acknowledge and agree that where a party processes personal data under or in connection with this Agreement it alone determines the purposes and means of such processing as a data controller. To the extent Consultant discloses, provides or otherwise makes available, personal data to Company under or in connection with the Agreement (“Shared Personal Data”), Consultant acknowledges that Company and its agents may process such Shared Personal Data for any purpose related to this Agreement, including for any purpose necessary to comply with applicable law. In connection with the Shared Personal Data, Consultant warrants that it: (a) has provided adequate notices to, and obtained valid consents from, the relevant individuals, in each case, to the extent necessary for Company or its agents to process the Shared Personal Data in connection with this Agreement which may include the transfer of the Shared Personal Data to Company outside of the European Economic Area (EEA); and (b) shall not, by act or omission, cause Company to violate any Data Protection Laws, notices provided to, or consents obtained from, data subjects

-6-


as result of processing the Shared Personal Data in connection with this Agreement. In addition, Consultant agrees to comply with applicable data protection and data privacy laws.

23.Counterparts.  This Agreement may be executed manually or by facsimile signature in two or more counterparts, each of which shall be deemed an original, and all of which together shall constitute but one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Consulting Agreement on the date first written above.  

CONSULTANT

Caren Mason

/s/

COMPANY

STAAR SURGICAL COMPANY

/s/
Aimee Weisner

 

 

-7-


 

 

EXHIBIT A

DUTIES OF CONSULTANT

 

Consultant shall provide advisory services in connection with the transition of her role, as requested from time to time by the Company’s CEO, members of the Board of Directors, and members of the Executive Management Team, which may include, without limitation, advice regarding corporate strategy, operations, and personnel.

 

EX-99.1 4 staa-ex991_60.htm EX-99.1 staa-ex991_60.htm

Exhibit 99.1

 

STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO

 

 

Ophthalmic industry executive Tom Frinzi has been appointed President & CEO of STAAR Surgical, effective January 1, 2023.

  

 

 

 

 

 

 

 

 

 

Caren Mason will be retiring from STAAR Surgical on December 31, 2022, after leading the company through a significant period of revitalization and growth for more than seven years.

 

LAKE FOREST, CA, December 19, 2022 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that President and Chief Executive Officer Caren Mason will be retiring December 31, 2022, after leading the company through a significant period of revitalization and growth for more than seven years. STAAR’s Board of Directors has appointed ophthalmic industry executive Thomas “Tom” G. Frinzi, current Board Chair of STAAR, to serve as President and CEO, effective January 1, 2023.

 

To ensure a seamless transition, Ms. Mason has agreed to serve in an advisory role through December 31, 2023.

 

"On behalf of the entire Board, I want to thank Caren for her exceptional tenure as STAAR’s President and CEO since March 2015,” said Aimee S. Weisner, Chair of the Board’s Nominating and Governance Committee. “Under Caren’s leadership, STAAR has achieved numerous significant milestones including accelerating average revenue growth above 25% over the past several years and gaining U.S. FDA approval of our EVO lenses earlier this year. At the same time, Caren has overseen a dramatic increase in shareholder value with shares of STAAR increasing in value by almost 10 times during her tenure. She leaves STAAR in an incredibly strong financial and market position.”

 

Ms. Mason was appointed President and Chief Executive Officer of STAAR in March 2015 after serving as an independent Director on STAAR’s Board of Directors since 2014. Prior to joining STAAR, Ms. Mason served as CEO and in other senior executive roles at numerous innovative healthcare, life sciences, diagnostic technology, and medical device companies.

 

“Serving as CEO of STAAR Surgical has been the highlight of my career,” said Ms. Mason. “I am proud of STAAR’s accomplishments under my leadership over the past seven years, and I am grateful for the many dedicated


 

 

professionals around the world who make STAAR such a phenomenal company. I look forward to watching STAAR’s continued success and have great confidence in Tom and the amazing STAAR leadership team.”

 

Mr. Frinzi was appointed to STAAR’s Board of Directors in June 2020 and has extensive experience in the ophthalmic and medical device industries at both large, well-established companies and innovative start-ups. He served as Worldwide President, Surgical for Johnson & Johnson’s Vision business, and previously served as Senior Vice President of Abbott Laboratories and President, Abbott Medical Optics (AMO). Prior to Abbott, he served as President and CEO of WaveTec Vision, a developer of surgical systems for eye surgery. He previously held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Chiron Vision.

 

“I am honored to be selected to lead STAAR as CEO and excited about our company’s future, especially our significant opportunity launching EVO ICL in the United States,” said Mr. Frinzi. “Caren has set the company on extremely strong footing, and I will be highly focused on continuing our global growth and ensuring STAAR continues to lead the industry with innovative lens-based solutions that offer freedom from glasses and contact lenses. We have an incredibly strong team, a life-transforming solution for patients, and we are well positioned to continue to deliver for patients and the physicians who serve them, while also driving value for our shareholders.”

 

“Tom is the ideal leader to serve as STAAR’s next CEO,” said Ms. Weisner. “He brings more than 40 years of ophthalmic and medical device experience to his stewardship of STAAR and has the vision and expertise to continue STAAR’s strong trajectory of growth and leadership position in implantable lenses for myopia. As Chair of the Board, Tom has been a significant contributor to STAAR’s success for more than two years, and we are confident he will excel as STAAR’s CEO.”

 

STAAR also announced today that it expects to achieve total net sales for the fourth quarter of 2022 in the range of $64 million to $66 million.

 

The Board has created the new role of Lead Independent Director, effective January 1, 2023, and appointed Mr. Stephen Farrell, Chair of the Audit Committee, to serve in that capacity. Effective with Ms. Mason’s retirement, STAAR’s Board reduced the total number of members from seven to six.

 

About STAAR Surgical

 

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™ product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Safe Harbor

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the fourth quarter of 2022. Important factors that could cause actual results to differ materially from those indicated by

2

 


 

 

such forward-looking statements include risks and uncertainties related to the COVID-19 pandemic and related public health measures, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of the COVID-19 pandemic on markets; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval, or to take enforcement action; international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure.

 

 

CONTACT:Investors and Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

 

 

3

 

GRAPHIC 5 ga4lcldyedjf000002.jpg GRAPHIC begin 644 ga4lcldyedjf000002.jpg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end GRAPHIC 6 ga4lcldyedjf000001.jpg GRAPHIC begin 644 ga4lcldyedjf000001.jpg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ga4lcldyedjf000003.jpg GRAPHIC begin 644 ga4lcldyedjf000003.jpg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staa-20221216.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 9 staa-20221216_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol(s) Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 10 staa-20221216_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Dec. 16, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 16, 2022
Entity Registrant Name STAAR Surgical Co
Entity Central Index Key 0000718937
Entity Emerging Growth Company false
Entity File Number 0-11634
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 95-3797439
Entity Address, Address Line One 25651 Atlantic Ocean Drive
Entity Address, City or Town Lake Forest
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92630
City Area Code 626
Local Phone Number 303-7902
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common
Trading Symbol(s) STAA
Name of each exchange on which registered NASDAQ
XML 12 staa-8k_20221216_htm.xml IDEA: XBRL DOCUMENT 0000718937 2022-12-16 2022-12-16 false 0000718937 8-K 2022-12-16 STAAR Surgical Co DE 0-11634 95-3797439 25651 Atlantic Ocean Drive Lake Forest CA 92630 626 303-7902 false false false false Common STAA NASDAQ false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports staa-8k_20221216.htm staa-20221216.xsd staa-20221216_lab.xml staa-20221216_pre.xml staa-ex101_7.htm staa-ex102_6.htm staa-ex991_60.htm http://xbrl.sec.gov/dei/2022 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "staa-8k_20221216.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "staa-8k_20221216.htm" ] }, "labelLink": { "local": [ "staa-20221216_lab.xml" ] }, "presentationLink": { "local": [ "staa-20221216_pre.xml" ] }, "schema": { "local": [ "staa-20221216.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "staa", "nsuri": "http://www.staar.com/20221216", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "staa-8k_20221216.htm", "contextRef": "C_0000718937_20221216_20221216", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "staa-8k_20221216.htm", "contextRef": "C_0000718937_20221216_20221216", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20221216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001564590-22-039439-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-039439-xbrl.zip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end